Detail akcie Halozyme Thrp online

Business Summary: Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Halozyme Therapeutics, Inc. revenues increased 35% to $264.9M. Net income increased 54% to $118.1M. Revenues reflect Royalties segment increase of 39% to $168.2M, Roche (rHuPH20) segment increase from $10.5M to $27M. Net income benefited from Research and development - Balancing val decrease of 27% to $11.6M (expense), Investment and other income increase of 37% to $6.8M (income).